Join to access to all OVN content. Join for Free
Leadership Lab: 5 Ways Biopharma Execs Can Restore Trust, Retain Talent After Layoffs
careers

Leadership Lab: 5 Ways Biopharma Execs Can Restore Trust, Retain Talent After Layoffs


Share This Article


Summary

In the latest installment of his column, Kaye/Bassman’s Michael Pietrack shares five ways leaders can help their teams after a layoff, from acknowledging emotions to reestablishing culture.

Welcome to Leadership Lab, a column dedicated to biopharma executives aiming to enhance their leadership skills and advance their careers. Every other month, Michael Pietrack, the practice lead for Kaye/Bassman’s pharma and biotech recruiting team and host of “The Pharmaverse Podcast,” shares a valuable leadership insight. 

In this column, we’ll discuss five ways leaders can help their team after a layoff. Those who follow these five imperatives are restoring trust with employees, which helps their companies retain talent.

The biopharmaceutical industry is undergoing a period of painful contraction. Clinical setbacks, shifting pipelines, economic headwinds and capital constraints have forced even the most promising companies to make difficult personnel decisions. While these decisions are often strategically sound, the impact on people is significant and long lasting.

For those who remain in leadership roles, the real challenge begins after the layoffs. Teams are now leaner, and team psychology is often fragile. What your employees need at this moment is not just a manager of tasks, but a true leader.

This is not leadership under normal conditions. This is leadership under pressure. And in these moments, five imperatives emerge for biopharma leaders committed to restoring trust and retaining talent.

1. Acknowledge the Emotions

Layoffs don’t just change head

counts, they change people. Those who remain often wrestle with survivor’s guilt, a blend of gratitude, anxiety and moral discomfort. If left unspoken, these emotions can quietly erode trust, motivation and, ultimately, retention.

Strong leaders name the moment for what it is. They ack

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
3 Things I wish I knew about being a MSL
Partner Avatar MSL Talk: Tom Caravela, Mitchell D’Rozario

3 Things I wish I knew about being a MSL

Article
The Great Resignation is Now The Great Hesitation
Partner Avatar Michael Pietrack

The Great Resignation is Now The Great Hesitation

Article
Leadership Lab: How To Spot When Employees Are About To Walk Away
Partner Avatar Michael Pietrack

Leadership Lab: How To Spot When Employees Are About To Walk Away

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Explore OVN